Page 13 - 《中国药科大学学报》2025年第5期

第 56 卷第 5 期 涂远博，等：肝脏器官芯片在成药性评价中的应用进展 545

[2] Van Norman GA. Limitations of animal studies for predicting chip: the convergence of microphysiological systems and
toxicity in clinical trials: is it time to rethink our current ap- organoids[J]. Front Cell Dev Biol, 2022, 10: 1043117.
proach[J]? JACC Basic Transl Sci, 2019, 4(7): 845-854. [17] Calamaio S, Serzanti M, Boniotti J, et al. Human iPSC-derived
[3] Farzaneh Z, Khojastehpour F, Keivan M, et al. Co-culture of 3D hepatic organoids in a miniaturized dynamic culture
liver parenchymal cells with non-parenchymal cells under 2D system[J]. Biomedicines, 2023, 11(8): 2114.
and 3D culture systems; A review[J]. Curr Stem Cell Res Ther, [18] Kogler S, Pedersen GM, Martínez-Ramírez F, et al. An FDA-
2023, 18(7): 904-916. validated, self-cleaning liquid chromatography-mass spectrome-
[4] Moradi E, Jalili-Firoozinezhad S, Solati-Hashjin M. Microflu- try system for determining small-molecule drugs and metabo-
idic organ-on-a-chip models of human liver tissue[J]. Acta Bio- lites in organoid/organ-on-chip medium[J]. Anal Chem, 2024,
mater, 2020, 116: 67-83. 96(29): 12129-12138.
[5] Fabre K, Berridge B, Proctor WR, et al. Introduction to a [19] Zhao Y, Kankala RK, Wang SB, et al. Multi-organs-on-chips:
manuscript series on the characterization and use of microphysi- towards long-term biomedical investigations[J]. Molecules,
ological systems (MPS) in pharmaceutical safety and ADME 2019, 24(4): 675.
applications[J]. Lab Chip, 2020, 20(6): 1049-1057. [20] Asif A, Park SH, Manzoor Soomro A, et al. Microphysiologi-
[6] Rumsey JW, Lorance C, Jackson M, et al. Classical comple- cal system with continuous analysis of albumin for hepatotoxic-
ment pathway inhibition in a “human-on-A-chip” model of au- ity modeling and drug screening[J]. J Ind Eng Chem, 2021, 98:
toimmune demyelinating neuropathies[J]. Adv Ther, 2022, 5(6): 318-326.
2200030. [21] Du K, Li SB, Li CP, et al. Modeling nonalcoholic fatty liver
[7] National Medical Products Administration Center for Drug disease on a liver lobule chip with dual blood supply[J]. Acta
Evaluation. Notice of the Center for Drug Evaluation of the Na- Biomater, 2021, 134: 228-239.
tional Medical Products Administration on the Release of the [22] Kostrzewski T, Snow S, Battle AL, et al. Modelling human liv-
“Technical Guidelines for Non-Clinical Research and Evalua- er fibrosis in the context of non-alcoholic steatohepatitis using a
tion of Gene Therapy Products (Trial)” and “Technical Guide- microphysiological system[J]. Commun Biol, 2021, 4(1): 1080.
lines for Non-Clinical Research of Genetically Modified Cell [23] Freag MS, Namgung B, Reyna Fernandez ME, et al. Human
Therapy Products (Trial)” (No. 49[2021])[EB/OL]. (2021-11- nonalcoholic steatohepatitis on a chip[J]. Hepatol Commun,
30)[2024-10-04]. https://www.cde.org.cn/main/news/viewInfo- 2020, 5(2): 217-233.
Common/41bc557bec23a6ebfb0e148cc989f041. [24] Lee J, Choi B, No DY, et al. A 3D alcoholic liver disease mod-
[8] Wu QR, Liu JF, Wang XH, et al. Organ-on-a-chip: recent el on a chip[J]. Integr Biol (Camb), 2016, 8(3): 302-308.
breakthroughs and future prospects[J]. Biomed Eng Online, [25] Nawroth JC, Petropolis DB, Manatakis DV, et al. Modeling al-
2020, 19(1): 9. cohol-associated liver disease in a human Liver-Chip[J]. Cell
[9] Tajeddin A, Mustafaoglu N. Design and fabrication of organ- Rep, 2021, 36(3): 109393.
on-chips: promises and challenges[J]. Micromachines (Basel), [26] Liu M, Yan Q, Sun Y, et al. A hepatocyte differentiation model
2021, 12(12): 1443. reveals two subtypes of liver cancer with different oncofetal
[10] Pisapia F, Balachandran W, Rasekh M. Organ-on-a-chip: de- properties and therapeutic targets[J]. Proc Natl Acad Sci USA,
sign and simulation of various microfluidic channel geometries 2020, 117(11): 6103-6113.
for the influence of fluid dynamic parameters[J]. Appl Sci, 2022, [27] Zou ZY, Lin Z, Wu CL, et al. Micro-engineered organoid-on-a-
12(8): 3829. chip based on mesenchymal stromal cells to predict im-
[11] Liu S, Cheng CL, Zhu LY, et al. Liver organoids: updates on munotherapy responses of HCC patients[J]. Adv Sci (Weinh),
generation strategies and biomedical applications[J]. Stem Cell 2023, 10(27): e2302640.
Res Ther, 2024, 15(1): 244. [28] Yang ZH, Zhou ZH, Si TX, et al. High throughput confined mi-
[12] Scheidecker B, Poulain S, Sugimoto M, et al. Dynamic, IPSC- gration microfluidic device for drug screening[J]. Small, 2023,
derived hepatic tissue tri-culture system for the evaluation of 19(16): e2207194.
liver physiology in vitro[J]. Biofabrication, 2024, 16(2). [29] Sharifi F, Yesil-Celiktas O, Kazan A, et al. A hepatocellular
doi:10.1088/1758-5090/ad30c5. carcinoma–bone metastasis-on-a-chip model for studying thy-
[13] Odanga JJ, Anderson SM, Breathwaite EK, et al. Characteriza- moquinone-loaded anticancer nanoparticles[J]. Bio Des Manuf,
tion of diseased primary human hepatocytes in an all-human 2020, 3(3): 189-202.
cell-based triculture system[J]. Sci Rep, 2024, 14(1): 6772. [30] Sun W, Chen YQ, Wang MF, et al. Study on drug resistance to
[14] Zhao ZX, Chen XY, Dowbaj AM, et al. Organoids[J]. Nat Rev tumor cell in oxygen gradient and co-culture microfluidic
Meth Primers, 2022, 2: 94. chip[J]. Chin J Anal Chem, 2020, 48(2): 180-186.
[15] Li Y, Xu C, Zhou XT, et al. DNA adductomics aided rapid [31] Lim J, Choi H, Ahn J, et al. 3D high-content culturing and drug
screening of genotoxic impurities using nucleosides and 3D bio- screening platform to study vascularized hepatocellular carcino-
printed human liver organoids[J]. Talanta, 2024, 273: 125902. ma in hypoxic condition[J]. Adv NanoBiomed Res, 2021, 1(12):
[16] Baptista LS, Porrini C, Kronemberger GS, et al. 3D organ-on-a- 2100078.